COSMIC project: consensus on the objectives of the metabolic syndrome in clinic
Juan Pedro-Botet 1 , Juan F Ascaso 2 3 , Vivencio Barrios 4 5 , Alejandro De la Sierra 6 , Javier Escalada 7 8 , Jesús Millán 9 , Jose M Mostaza 10 , Pablo Pérez-Martínez 8 11 , Xavier Pintó 8 12 , Jordi Salas-Salvadó 8 13 , Pedro Valdivielso 14
Metabolic syndrome (MetS), a disorder with a high and growing prevalence, is a recognized risk factor for cardiovascular disease (CVD) and type 2 diabetes.
It is a constellation of clinical and metabolic risk factors that include abdominal obesity, dyslipidemia, glucose intolerance, and hypertension. Unfortunately, MetS is typically underrecognized, and there is great heterogeneity in its management, which can hamper clinical decision-making and be a barrier to achieving the therapeutic goals of CVD and diabetes prevention.
Although no single treatment for MetS as a whole currently exists, management should be targeted at treating the conditions contributing to it and possibly reversing the risk factors. All this justifies the need to develop recommendations that adapt existing knowledge to clinical practice in our healthcare system. In this regard, professionals from different scientific societies who are involved in the management of the different MetS components reviewed the available scientific evidence focused basically on therapeutic aspects of MetS and developed a consensus document to establish recommendations on therapeutic goals that facilitate their homogenization in clinical decision-making.